Analyst’s Disclosure:I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article. Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or a ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2025 OR (State or other jurisdiction of (I.R.S. Employer incorporation or organization) Identification No.) INDIANA 82-5497352 2500 INNOVATION WAY, GREENFIELD, INDIANA 46140 (Address and zip code of principal executive offices) Registrant's telephone number, including area code (877) 352-6261 ☐ TRAN ...

Elanco Animal Health (ELAN) Q2 2025 Earnings Call August 07, 2025 08:00 AM ET Company ParticipantsTiffany Kanaga - VP - Investor Relations & ESGJeffrey Simmons - President, CEO & DirectorBob VanHimbergen - EVP & CFOJonathan Block - Managing DirectorDaniel Clark - VP - Equity ResearchMichael Ryskin - Managing DirectorAndrea Alfonso - Executive DirectorConference Call ParticipantsNone - AnalystRoss Sparenblek - Equity Research AnalystNavann Ty - Lead Analyst - HealthcareErin Wright - Senior Equity Research An ...

Elanco Animal Health Incorporated (ELAN) came out with quarterly earnings of $0.26 per share, beating the Zacks Consensus Estimate of $0.2 per share. This compares to earnings of $0.3 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of +30.00%. A quarter ago, it was expected that this company would post earnings of $0.31 per share when it actually produced earnings of $0.37, delivering a surprise of +19.35%.Over the last four quar ...

D 2025 Earnings – Second Quarter August 7, 2025 2025 | Q2 Earnings Notices and Disclaimers Forward-Looking Statements. This presentation contains forward-looking statements within the meaning of the federal securities laws, including, without limitation, statements concerning product launches and revenue from such products, our 2025 full year and third quarter guidance, long-term expectations, our expectations regarding debt levels, and expectations regarding our industry and our operations, performance and ...

Exhibit 99.1 FOR IMMEDIATE RELEASE Investor Contact: Tiffany Kanaga (765) 740-0314 or tiffany.kanaga@elancoah.com Media Contact: Colleen Parr Dekker (317) 989-7011 or colleen.dekker@elancoah.com Elanco Animal Health Reports Second Quarter 2025 Results Raising Full Year Outlook and Innovation Target, Improving Year-End Net Leverage Ratio Target GREENFIELD, Ind (August 7, 2025) - Elanco Animal Health Incorporated (NYSE: ELAN) today reported financial results for the second quarter of 2025, provided guidance f ...

Core Insights - Elanco Animal Health has received approval from the European Commission for Zenrelia™ (ilunocitinib), marking a significant milestone in the EU canine dermatology market [1][2][3] Group 1: Product Approval and Market Impact - Zenrelia is recognized as a highly effective, convenient, and safe once-daily oral JAK inhibitor for controlling pruritus associated with allergic dermatitis and atopic dermatitis in dogs aged at least 12 months [2][3] - The approval reinforces Elanco's position as a leader in pet health innovation and is expected to enhance the treatment options available for veterinarians and pet owners in Europe [3][4] Group 2: Clinical Study and Efficacy - A head-to-head non-inferiority study against the market leader, Apoquel, involved 338 client-owned dogs and demonstrated that Zenrelia is at least as effective as the incumbent JAK inhibitor at the primary endpoint on Day 28 [4] - The study results have been published in the peer-reviewed journal Veterinary Dermatology, further validating the product's efficacy [4] Group 3: Commercial Strategy and Launch - Elanco's commercial teams are prepared for an immediate product launch, with supply availability expected in the third quarter of 2025 [4][8] - Zenrelia will join Elanco's growing pet health portfolio in Europe, which includes other products like AdTab, Credelio, and Galliprant [4]

Core Insights - Elanco Animal Health Incorporated (ELAN) is currently positioned as a more attractive investment compared to U.S. Physical Therapy (USPH) based on Zacks Rank and valuation metrics [3][7] Valuation Metrics - ELAN has a forward P/E ratio of 17.91, significantly lower than USPH's forward P/E of 30.39 [5] - The PEG ratio for ELAN is 2.93, while USPH's PEG ratio stands at 3.66, indicating ELAN's better valuation relative to its expected earnings growth [5] - ELAN's P/B ratio is 1.17, compared to USPH's P/B of 2.3, further supporting ELAN's superior valuation metrics [6] Earnings Outlook - ELAN has a Zacks Rank of 2 (Buy), reflecting positive revisions in earnings estimates, while USPH has a Zacks Rank of 5 (Strong Sell), indicating a less favorable earnings outlook [3][7] - The improving earnings outlook for ELAN is a critical factor for value investors [3]

GREENFIELD, Ind., July 10, 2025 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE: ELAN) will announce its second quarter 2025 financial results on Thursday, August 7, 2025. Elanco will also conduct a conference call on that day with the investment community and media to provide further details about the company's performance.The conference call will begin at 8:00 a.m. Eastern time. Investors, media, and the general public can access a live webcast of the conference call through the link posted on Ela ...

In Canine Influenza Virus (CIV) studies, TruCan Ultra CIV was shown to be highly effective in protecting dogs' lungs and improving clinical signs: Zero vaccinated dogs developed lung lesions post H3N2 challenge2 100% neutralization of 33 currently circulating CIV field isolates1 Proven to reduce viral shedding2,5 Proven safe across multiple breed and ages in field safety study5 "With the recent USDA approval for TruCan Ultra CIV, Elanco continues to lead the charge in innovative animal health solutions," ...